Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
- Mochida Unveils New 3-Year Biz Targets, Price Revisions, Generic Penetration Weigh
April 2, 2015
- Kenichi Fujita Becomes President of Taisho Toyama
April 2, 2015
- Eli Lilly to Solely Distribute Cymbalta; Shionogi to Enhance Detailing Activities
April 2, 2015
- MTPC Licenses VMAT2 Inhibitor from Neurocrine Biosciences
April 2, 2015
- Takeda Transfers Mizusawa Shares to Osaka Gas Chemicals for 4.3 Billion Yen
April 2, 2015
- SGLT-2 Inhibitors Represent Only 0.6% of Diabetes Prescriptions at DPC Hospitals: Survey
April 1, 2015
- Lupin Group’s Kyowa Sees Japan-India Collaboration as Key to Survival: Pres.
April 1, 2015
- Takecab Ranks 1st for Second Month in a Row: Anterio February Ranking
April 1, 2015
- Ajinomoto, Kissei Tie Up to Develop, Market Ulcerative Colitis Treatments
April 1, 2015
- Denka Seiken Develops Prototype of Rapid Diagnostic Agent for Ebola Virus
April 1, 2015
- Fujifilm to Buy US iPS Cell Manufacturer Cellular Dynamics
March 31, 2015
- Eisai’s Lenvima Gains Positive Opinion from CHMP
March 31, 2015
- Taisho Partners with Teijin to Comarket Patch Formulation Containing S-Flurbiprofen
March 31, 2015
- Hisamitsu to Rejuvenate Management with Nakatomi Junior as President
March 30, 2015
- Ichiro Otsuka Becomes Chairman of Otsuka Holdings
March 30, 2015
- Pfizer Looking for Drug Discovery Partnerships with Domestic Drug Makers
March 30, 2015
- Genzyme Japan Receives Approval for Japan’s 1st Oral Gaucher’s Disease Treatment Cerdelga
March 30, 2015
- E Keppra Filed for Generalized Tonic-Clonic Seizures: Otsuka, UCB Japan
March 30, 2015
- Takeda Seeks Japan Approval for Single-Packs Containing Takecab for H. pylori Eradication
March 27, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…